Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 173139

AbstractMaterial and MethodsResultsDiscussionConclusionAcknowledgementReferencesDOI and Others
Article in PDF How to Cite Citation Manager Readers' Comments (0) Audio Visual Article Statistics Link to PUBMED Print this Article Send to a Friend
Advertisers Access Statistics Resources

Dr Mohan Z Mani

"Thank you very much for having published my article in record time.I would like to compliment you and your entire staff for your promptness, courtesy, and willingness to be customer friendly, which is quite unusual.I was given your reference by a colleague in pathology,and was able to directly phone your editorial office for clarifications.I would particularly like to thank the publication managers and the Assistant Editor who were following up my article. I would also like to thank you for adjusting the money I paid initially into payment for my modified article,and refunding the balance.
I wish all success to your journal and look forward to sending you any suitable similar article in future"



Dr Mohan Z Mani,
Professor & Head,
Department of Dermatolgy,
Believers Church Medical College,
Thiruvalla, Kerala
On Sep 2018




Prof. Somashekhar Nimbalkar

"Over the last few years, we have published our research regularly in Journal of Clinical and Diagnostic Research. Having published in more than 20 high impact journals over the last five years including several high impact ones and reviewing articles for even more journals across my fields of interest, we value our published work in JCDR for their high standards in publishing scientific articles. The ease of submission, the rapid reviews in under a month, the high quality of their reviewers and keen attention to the final process of proofs and publication, ensure that there are no mistakes in the final article. We have been asked clarifications on several occasions and have been happy to provide them and it exemplifies the commitment to quality of the team at JCDR."



Prof. Somashekhar Nimbalkar
Head, Department of Pediatrics, Pramukhswami Medical College, Karamsad
Chairman, Research Group, Charutar Arogya Mandal, Karamsad
National Joint Coordinator - Advanced IAP NNF NRP Program
Ex-Member, Governing Body, National Neonatology Forum, New Delhi
Ex-President - National Neonatology Forum Gujarat State Chapter
Department of Pediatrics, Pramukhswami Medical College, Karamsad, Anand, Gujarat.
On Sep 2018




Dr. Kalyani R

"Journal of Clinical and Diagnostic Research is at present a well-known Indian originated scientific journal which started with a humble beginning. I have been associated with this journal since many years. I appreciate the Editor, Dr. Hemant Jain, for his constant effort in bringing up this journal to the present status right from the scratch. The journal is multidisciplinary. It encourages in publishing the scientific articles from postgraduates and also the beginners who start their career. At the same time the journal also caters for the high quality articles from specialty and super-specialty researchers. Hence it provides a platform for the scientist and researchers to publish. The other aspect of it is, the readers get the information regarding the most recent developments in science which can be used for teaching, research, treating patients and to some extent take preventive measures against certain diseases. The journal is contributing immensely to the society at national and international level."



Dr Kalyani R
Professor and Head
Department of Pathology
Sri Devaraj Urs Medical College
Sri Devaraj Urs Academy of Higher Education and Research , Kolar, Karnataka
On Sep 2018




Dr. Saumya Navit

"As a peer-reviewed journal, the Journal of Clinical and Diagnostic Research provides an opportunity to researchers, scientists and budding professionals to explore the developments in the field of medicine and dentistry and their varied specialities, thus extending our view on biological diversities of living species in relation to medicine.
‘Knowledge is treasure of a wise man.’ The free access of this journal provides an immense scope of learning for the both the old and the young in field of medicine and dentistry as well. The multidisciplinary nature of the journal makes it a better platform to absorb all that is being researched and developed. The publication process is systematic and professional. Online submission, publication and peer reviewing makes it a user-friendly journal.
As an experienced dentist and an academician, I proudly recommend this journal to the dental fraternity as a good quality open access platform for rapid communication of their cutting-edge research progress and discovery.
I wish JCDR a great success and I hope that journal will soar higher with the passing time."



Dr Saumya Navit
Professor and Head
Department of Pediatric Dentistry
Saraswati Dental College
Lucknow
On Sep 2018




Dr. Arunava Biswas

"My sincere attachment with JCDR as an author as well as reviewer is a learning experience . Their systematic approach in publication of article in various categories is really praiseworthy.
Their prompt and timely response to review's query and the manner in which they have set the reviewing process helps in extracting the best possible scientific writings for publication.
It's a honour and pride to be a part of the JCDR team. My very best wishes to JCDR and hope it will sparkle up above the sky as a high indexed journal in near future."



Dr. Arunava Biswas
MD, DM (Clinical Pharmacology)
Assistant Professor
Department of Pharmacology
Calcutta National Medical College & Hospital , Kolkata




Dr. C.S. Ramesh Babu
" Journal of Clinical and Diagnostic Research (JCDR) is a multi-specialty medical and dental journal publishing high quality research articles in almost all branches of medicine. The quality of printing of figures and tables is excellent and comparable to any International journal. An added advantage is nominal publication charges and monthly issue of the journal and more chances of an article being accepted for publication. Moreover being a multi-specialty journal an article concerning a particular specialty has a wider reach of readers of other related specialties also. As an author and reviewer for several years I find this Journal most suitable and highly recommend this Journal."
Best regards,
C.S. Ramesh Babu,
Associate Professor of Anatomy,
Muzaffarnagar Medical College,
Muzaffarnagar.
On Aug 2018




Dr. Arundhathi. S
"Journal of Clinical and Diagnostic Research (JCDR) is a reputed peer reviewed journal and is constantly involved in publishing high quality research articles related to medicine. Its been a great pleasure to be associated with this esteemed journal as a reviewer and as an author for a couple of years. The editorial board consists of many dedicated and reputed experts as its members and they are doing an appreciable work in guiding budding researchers. JCDR is doing a commendable job in scientific research by promoting excellent quality research & review articles and case reports & series. The reviewers provide appropriate suggestions that improve the quality of articles. I strongly recommend my fraternity to encourage JCDR by contributing their valuable research work in this widely accepted, user friendly journal. I hope my collaboration with JCDR will continue for a long time".



Dr. Arundhathi. S
MBBS, MD (Pathology),
Sanjay Gandhi institute of trauma and orthopedics,
Bengaluru.
On Aug 2018




Dr. Mamta Gupta,
"It gives me great pleasure to be associated with JCDR, since last 2-3 years. Since then I have authored, co-authored and reviewed about 25 articles in JCDR. I thank JCDR for giving me an opportunity to improve my own skills as an author and a reviewer.
It 's a multispecialty journal, publishing high quality articles. It gives a platform to the authors to publish their research work which can be available for everyone across the globe to read. The best thing about JCDR is that the full articles of all medical specialties are available as pdf/html for reading free of cost or without institutional subscription, which is not there for other journals. For those who have problem in writing manuscript or do statistical work, JCDR comes for their rescue.
The journal has a monthly publication and the articles are published quite fast. In time compared to other journals. The on-line first publication is also a great advantage and facility to review one's own articles before going to print. The response to any query and permission if required, is quite fast; this is quite commendable. I have a very good experience about seeking quick permission for quoting a photograph (Fig.) from a JCDR article for my chapter authored in an E book. I never thought it would be so easy. No hassles.
Reviewing articles is no less a pain staking process and requires in depth perception, knowledge about the topic for review. It requires time and concentration, yet I enjoy doing it. The JCDR website especially for the reviewers is quite user friendly. My suggestions for improving the journal is, more strict review process, so that only high quality articles are published. I find a a good number of articles in Obst. Gynae, hence, a new journal for this specialty titled JCDR-OG can be started. May be a bimonthly or quarterly publication to begin with. Only selected articles should find a place in it.
An yearly reward for the best article authored can also incentivize the authors. Though the process of finding the best article will be not be very easy. I do not know how reviewing process can be improved. If an article is being reviewed by two reviewers, then opinion of one can be communicated to the other or the final opinion of the editor can be communicated to the reviewer if requested for. This will help one’s reviewing skills.
My best wishes to Dr. Hemant Jain and all the editorial staff of JCDR for their untiring efforts to bring out this journal. I strongly recommend medical fraternity to publish their valuable research work in this esteemed journal, JCDR".



Dr. Mamta Gupta
Consultant
(Ex HOD Obs &Gynae, Hindu Rao Hospital and associated NDMC Medical College, Delhi)
Aug 2018




Dr. Rajendra Kumar Ghritlaharey

"I wish to thank Dr. Hemant Jain, Editor-in-Chief Journal of Clinical and Diagnostic Research (JCDR), for asking me to write up few words.
Writing is the representation of language in a textual medium i e; into the words and sentences on paper. Quality medical manuscript writing in particular, demands not only a high-quality research, but also requires accurate and concise communication of findings and conclusions, with adherence to particular journal guidelines. In medical field whether working in teaching, private, or in corporate institution, everyone wants to excel in his / her own field and get recognised by making manuscripts publication.


Authors are the souls of any journal, and deserve much respect. To publish a journal manuscripts are needed from authors. Authors have a great responsibility for producing facts of their work in terms of number and results truthfully and an individual honesty is expected from authors in this regards. Both ways its true "No authors-No manuscripts-No journals" and "No journals–No manuscripts–No authors". Reviewing a manuscript is also a very responsible and important task of any peer-reviewed journal and to be taken seriously. It needs knowledge on the subject, sincerity, honesty and determination. Although the process of reviewing a manuscript is a time consuming task butit is expected to give one's best remarks within the time frame of the journal.
Salient features of the JCDR: It is a biomedical, multidisciplinary (including all medical and dental specialities), e-journal, with wide scope and extensive author support. At the same time, a free text of manuscript is available in HTML and PDF format. There is fast growing authorship and readership with JCDR as this can be judged by the number of articles published in it i e; in Feb 2007 of its first issue, it contained 5 articles only, and now in its recent volume published in April 2011, it contained 67 manuscripts. This e-journal is fulfilling the commitments and objectives sincerely, (as stated by Editor-in-chief in his preface to first edition) i e; to encourage physicians through the internet, especially from the developing countries who witness a spectrum of disease and acquire a wealth of knowledge to publish their experiences to benefit the medical community in patients care. I also feel that many of us have work of substance, newer ideas, adequate clinical materials but poor in medical writing and hesitation to submit the work and need help. JCDR provides authors help in this regards.
Timely publication of journal: Publication of manuscripts and bringing out the issue in time is one of the positive aspects of JCDR and is possible with strong support team in terms of peer reviewers, proof reading, language check, computer operators, etc. This is one of the great reasons for authors to submit their work with JCDR. Another best part of JCDR is "Online first Publications" facilities available for the authors. This facility not only provides the prompt publications of the manuscripts but at the same time also early availability of the manuscripts for the readers.
Indexation and online availability: Indexation transforms the journal in some sense from its local ownership to the worldwide professional community and to the public.JCDR is indexed with Embase & EMbiology, Google Scholar, Index Copernicus, Chemical Abstracts Service, Journal seek Database, Indian Science Abstracts, to name few of them. Manuscriptspublished in JCDR are available on major search engines ie; google, yahoo, msn.
In the era of fast growing newer technologies, and in computer and internet friendly environment the manuscripts preparation, submission, review, revision, etc and all can be done and checked with a click from all corer of the world, at any time. Of course there is always a scope for improvement in every field and none is perfect. To progress, one needs to identify the areas of one's weakness and to strengthen them.
It is well said that "happy beginning is half done" and it fits perfectly with JCDR. It has grown considerably and I feel it has already grown up from its infancy to adolescence, achieving the status of standard online e-journal form Indian continent since its inception in Feb 2007. This had been made possible due to the efforts and the hard work put in it. The way the JCDR is improving with every new volume, with good quality original manuscripts, makes it a quality journal for readers. I must thank and congratulate Dr Hemant Jain, Editor-in-Chief JCDR and his team for their sincere efforts, dedication, and determination for making JCDR a fast growing journal.
Every one of us: authors, reviewers, editors, and publisher are responsible for enhancing the stature of the journal. I wish for a great success for JCDR."



Thanking you
With sincere regards
Dr. Rajendra Kumar Ghritlaharey, M.S., M. Ch., FAIS
Associate Professor,
Department of Paediatric Surgery, Gandhi Medical College & Associated
Kamla Nehru & Hamidia Hospitals Bhopal, Madhya Pradesh 462 001 (India)
E-mail: drrajendrak1@rediffmail.com
On May 11,2011




Dr. Shankar P.R.

"On looking back through my Gmail archives after being requested by the journal to write a short editorial about my experiences of publishing with the Journal of Clinical and Diagnostic Research (JCDR), I came across an e-mail from Dr. Hemant Jain, Editor, in March 2007, which introduced the new electronic journal. The main features of the journal which were outlined in the e-mail were extensive author support, cash rewards, the peer review process, and other salient features of the journal.
Over a span of over four years, we (I and my colleagues) have published around 25 articles in the journal. In this editorial, I plan to briefly discuss my experiences of publishing with JCDR and the strengths of the journal and to finally address the areas for improvement.
My experiences of publishing with JCDR: Overall, my experiences of publishing withJCDR have been positive. The best point about the journal is that it responds to queries from the author. This may seem to be simple and not too much to ask for, but unfortunately, many journals in the subcontinent and from many developing countries do not respond or they respond with a long delay to the queries from the authors 1. The reasons could be many, including lack of optimal secretarial and other support. Another problem with many journals is the slowness of the review process. Editorial processing and peer review can take anywhere between a year to two years with some journals. Also, some journals do not keep the contributors informed about the progress of the review process. Due to the long review process, the articles can lose their relevance and topicality. A major benefit with JCDR is the timeliness and promptness of its response. In Dr Jain's e-mail which was sent to me in 2007, before the introduction of the Pre-publishing system, he had stated that he had received my submission and that he would get back to me within seven days and he did!
Most of the manuscripts are published within 3 to 4 months of their submission if they are found to be suitable after the review process. JCDR is published bimonthly and the accepted articles were usually published in the next issue. Recently, due to the increased volume of the submissions, the review process has become slower and it ?? Section can take from 4 to 6 months for the articles to be reviewed. The journal has an extensive author support system and it has recently introduced a paid expedited review process. The journal also mentions the average time for processing the manuscript under different submission systems - regular submission and expedited review.
Strengths of the journal: The journal has an online first facility in which the accepted manuscripts may be published on the website before being included in a regular issue of the journal. This cuts down the time between their acceptance and the publication. The journal is indexed in many databases, though not in PubMed. The editorial board should now take steps to index the journal in PubMed. The journal has a system of notifying readers through e-mail when a new issue is released. Also, the articles are available in both the HTML and the PDF formats. I especially like the new and colorful page format of the journal. Also, the access statistics of the articles are available. The prepublication and the manuscript tracking system are also helpful for the authors.
Areas for improvement: In certain cases, I felt that the peer review process of the manuscripts was not up to international standards and that it should be strengthened. Also, the number of manuscripts in an issue is high and it may be difficult for readers to go through all of them. The journal can consider tightening of the peer review process and increasing the quality standards for the acceptance of the manuscripts. I faced occasional problems with the online manuscript submission (Pre-publishing) system, which have to be addressed.
Overall, the publishing process with JCDR has been smooth, quick and relatively hassle free and I can recommend other authors to consider the journal as an outlet for their work."



Dr. P. Ravi Shankar
KIST Medical College, P.O. Box 14142, Kathmandu, Nepal.
E-mail: ravi.dr.shankar@gmail.com
On April 2011
Anuradha

Dear team JCDR, I would like to thank you for the very professional and polite service provided by everyone at JCDR. While i have been in the field of writing and editing for sometime, this has been my first attempt in publishing a scientific paper.Thank you for hand-holding me through the process.


Dr. Anuradha
E-mail: anuradha2nittur@gmail.com
On Jan 2020

Important Notice

Original article / research
Year : 2012 | Month : June | Volume : 6 | Issue : 5 | Page : 783 - 786 Full Version

A Prospective, Double-blinded, Crossover Study to Determine the Equivalence of the Serum Levels and the Peak Level Toxicity of Diphenylhydantoin (EptoinR)


Published: June 1, 2012 | DOI: https://doi.org/10.7860/JCDR/2012/.2230
S. Bhuvaneshwari, Sujith Chandy, Sudhir Kumar,

1. Department of Pharmacology, Christian Medical College, Vellore, India. 2. Department of Neurology, Christian Medical College, Vellore, India. 3. Department of Clinical Pharmacology, Christian Medical College, Vellore, India.

Correspondence Address :
Dr. S. Bhuvaneshwari
A3, Fourth Floor, Ranga Castle, Kannapiran Mill Road,
Sowripalayam, Coimbatore, India - 641028.
Phone numbers: 98655 61463
E-mail: su_bhuvans@yahoo.co.in

Abstract

Context: In India, phenytoin is often prescribed as twice daily or thrice daily dosage schedules. In the West, this practice has been changed to a once daily regimen in most of the cases. Can we in India follow suit? Is our physical and genetic make up with regards to the phenytoin pharmacokinetics different? Does this necessitate a multiple dosing regimen to avoid adverse effects or even breakthrough seizures?
Aims:
This study was aimed at comparing 300mg once daily of phenytoin and 100mg tid of phenytoin in terms of its adverse effects, peak and trough serum concentrations.
Settings and Design:
Out patients attending the Neurology Department, Christian Medical College, Vellore, India. This was a prospective, randomized, double blinded, crossover study.
Methods and Materials:
Twenty-four patients were enrolled into the study. An informed consent was taken from them. Their liver and renal functions were checked. Their basal phenytoin levels were also estimated. Once the preliminary tests were found to be normal, the patients were inducted randomly into one of the two treatment arms, either 300mg once daily or 100mg thrice daily. Each arm was given for a 2 week period. Adverse effects were looked for and the peak and trough phenytoin concentrations were estimated.
Statistical Analysis Used:
The mean, SD and the P values were obtained by the Per Protocol and the ITT (Intention to Treat) analysis of the trough and peak serum levels by using Wilcoxon’s signed rank test.
Results:
One patient experienced an adverse effect in the once daily regimen as compared to no adverse effects in the tid regimen. The adverse effect was not consequential to the patient. Statistically, the trough concentrations were not significantly different between the regimens, although the peak concentrations of the once daily regimen were significantly higher.
Conclusions:
In conclusion, it can be said that the once daily regimen can be prescribed for Indian patients with epilepsy.

Keywords

Phenytoin, Dosing, Serum, Trough, Peak

INTRODUCTION
Phenytoin is one of the most commonly prescribed anti epileptic medications among physicians in India. Depending upon the patients’ age, weight and disease severity, phenytoin is being prescribed at various dosages. Many physicians, for fear of the adverse effects and the toxicity of phenytoin, advocate multiple frequency dosing. This fear may be because phenytoin has zero order kinetics.

Initially, phenytoin was administered in 2-4 divided doses throughout the world. Later, pharmacokinetics brought to light the drug half-lives and information on how these could be used to optimize the dosage regimens. Phenytoin has a variable, dose dependent half-life, but the mean is approximately 22 hours (1). Due to this relatively long half-life, questions were asked. Can phenytoin be given as a once daily dose? What effect will this have on the blood levels and the clinical toxicity profile of the patients? A further point which had to be considered was that a thrice-daily regimen often led to greater non-compliance than a once daily regimen (2).

Various studies which were done abroad (3),(4),(5) showed that once daily regimens could be given to epileptic patients. This information couldn’t be transcribed directly to the Indian patients, since for some compounds, the metabolism differed between the eastern and the Western patients (6).

This paper reports the results of a preliminary study which was done to assess the feasibility of a 300mg once daily dose of phenytoin as compared to a 100mg thrice daily dose in relation to the adverse effects as well as the peak and trough serum levels of Phenytoin.

Material and Methods

Study Design
A prospective, randomized, double blinded, crossover study
Sample Size Based on previous data (7), the mean (±SD) serum level was found to be 10.0 μg/ml (± 5.3). By allowing upto a 3 μg/ml difference as being similar (equal), and by taking the alpha and beta errors at a 5 % and 20% level, the sample size for a crossover study was calculated to be 48 patients in each arm. However, it being a cross over study, 24 patients were needed in total.
Inclusion Criteria
1. Patients between 18 years and 55 years of age.
2. Patients who received a total of 300mg phenytoin as Eptoin daily, for at least one month prior to their entry in the study.
Exclusion Criteria
1. Abnormal liver or kidney functions.
2. Patients who had seizures within one month prior to their entry into the study.
3. Patients having other systemic diseases.
4. Patients who were on any other anticonvulsant drugs concurrently.
5. Patients who were on other drugs which produced an interaction,
such as chloramphenicol. disulfiram, isoniazid, dicoumarol
and sulfonamides.
Methodology
• The ethical and research committee clearance was sanctioned, following which 24 patients were enrolled into the study, based on the inclusion and exclusion criteria.
• Detailed explanations and implications of the study were given to the subjects and their relatives. Their informed consent was taken. Their liver and renal functions were checked. Their basal phenytoin levels were also estimated. Once these preliminary steps were undertaken and everything was found to be normal, the patients were inducted into either of the 2 treatment arms, based on a random allotment. Each arm was given for a two-week period, after which a crossover format was followed. The treatment arms which were followed were:
Schedule A: Morning - One dose of 300mg Phenytoin + One 100mg placebo
Afternoon - One 100mg placebo
Night - One 100mg placebo
Schedule B: Morning - One dose of 100mg Phenytoin + One 300mg placebo
Afternoon - One dose of 100mg Phenytoin
Night - One dose of 100mg phenytoin
• A double blinded protocol was followed throughout the study. The patients were asked to report to the hospital at the end of the two-week treatment arms. During that time, the compliance cards which were given to them beforehand were checked. Once full compliance of the prescribed regimen was assured, the trough and peak serum concentrations of Phenytoin were measured. During the assumed peak concentration period, a detailed neurological evaluation was conducted to determine the features of the peak level toxicity of Phenytoin. If any patient was found to have such a feature, the patient was withdrawn from the study in accordance with the ethical guidelines.
Timing of the Blood Samples For the trough level–7 ml of blood was taken at 8 AM before taking the morning dose of phenytoin For the peak level–7 ml of blood was taken 4 hours after the morning dose
Procedure for Measuring the Drug Levels in Plasma
The concentration of phenytoin was measured by the method of Dill (8). The serum specimens were collected and kept frozen 784until they were analyzed . The high and low quality controls were stored alongside the patients’ specimens. This ensured that the standards, quality controls and the specimens were kept under the same conditions.

Results

(Table/Fig 1):
Adverse Effects (Table/Fig 1)
Regimen A (300mg once daily) – 1/24 - One patient had dizziness and nystagmus Regimen B (100mg tid) – 0/24
Serum Levels
The mean, SD and the P values were obtained by the Per Protocol and the ITT (Intention to Treat) analysis of the trough and peak serum levels by using Wilcoxon’s signed rank test (Table/Fig 2).
Inference
There seemed to be very little difference in terms of the adverse effects between both the regimens. The patient who developed an adverse effect with 300mg once daily had only a mild dizziness and nystagmus, which may not have been a problem if the patients had taken a night dosage. At 5% level of significance, there was no difference between the trough levels of both the regimens. At 5% level of significance, there was a difference between the peak levels of both the regimens, with the 300mg once daily regimen having a higher peak level. The clinical relevance of the difference in the peak levels was however diminished, since the adverse effect profile of both the regimens had very little to distinguish between them.(Table/Fig 2)
24 patients were enrolled into the study. One patient was withdrawn from the study due to development of nystagmus. Another patient was lost to follow up.

Discussion

It has been thought that the administration of the daily dose requirement once a day could produce peak serum concentrations which were associated with the toxicity of phenytoin. A peak absorption usually occurs four to 8 hours following phenytoin administration of the drug. Another reason which was given for the reticence in prescribing a once a day dosage was that the serum trough concentrations could become sub-therapeutic. This could led to breakthrough seizures. The specimen samples for the drug assays were obtained at 4 hours and 24 hours after the drug was administered. This study showed that there was no significant difference between the trough levels of both the regimens. Therefore, a once daily dose had not lead to sub-therapeutic trough concentrations. There was a significant statistical difference between the peak concentrations of the two dosage regimens, with the 300-mg once daily regimen having a higher mean peak value. The clinical significance of this with regards to the toxic effects was however diminished, since the adverse effect profile of both the dosage regimens were similar. Buchanan et al., (9) also supported the finding, that the average level which was obtained 4 hours after the administration of phenytoin (11.95 μg/ml) approximated the average level which was obtained just prior to the dosage (11.49 μg/ml), with 300mg of phenytoin being given as a single dose. In another study, he had indicated that the Css mean was 8.23μg/ml for the single daily dose group and that it was 8.83 μg/ml for the divided dose group. Statistical testing demonstrated no difference between the two levels (3). In the current study, out of 24 cases, eight subjects had a Cmax above 20 μg/ml in the single dose regimen, as compared to 3 who were on the divided dose regimen. Amongst those patients whose Cmax was above the therapeutic range, only one patient presented with a complaint of mild toxicity from the single dose group. Buchanan et al., (9) indicated that out of 13 patients, only one had a Cmax within the range of 20-25 μg/ml. On neurological examination, except for significant nystagmus, no other signs of toxicity were found and the patient did not complain of any side effects. It was found that this patient had persistent plasma levels which were in the toxic range, on admission and throughout the study, while 300 mg of phenytoin was given a single dose. In another study (10), he found that more episodes of nystagmus were recorded for the single dose group than for the divided dose group. However, the incidence of nystagmus for both the groups exceeded the levels which were seen in the clinical practice. Nystagmus occurred mostly at or above a serum level of 20 μg/ml. But none of these patients even approached this value. So, a particular correlation between the blood levels and the nystagmus could not be detected there. The single dose administration of phenytoin has the clinical application of motivating the patients to comply with their dosage schedule as instructed. Motivation and compliance are known to be the problem areas (11). This may be because active adults and school age children may find it inconvenient to take medications periodically throughout the day. Finally, the single dose administration could decrease the nursing costs for an institution which cared for a large number of epileptic patients. This study indicated that the two dosage schedules were pharmacologically equivalent. However, the prescribing physician for each individual patient must make the final decision concerning the frequency of the dosage.
Limitations of the study
This study was conducted in an outpatient setting. If this had been conducted in an inpatient department, the time at which the tablet was taken during the entire study period could have been recorded and other issues which were in compliance of the medication could have been brought out. In this study, the blood samples were taken at only two time points, that is, at the peak and the trough times. These two time points were the basic minimum and they were adequate to achieve the objectives of this study. However, in a kinetic study, it would have been ideal to take repeated samples so that the AUCs could be measured. This would make the study complete and provide comprehensive evidence to support the final inference In this study, the phenytoin levels were assayed only in the blood. The levels of phenytoin and its metabolite could have been assayed in the urine also. Measuring serum protein would have been helpful in ruling out malnutrition and other co-morbidities which could interfere with the phenytoin levels. The sample size for this study was small. Having a larger sample size would have provided more support to the inference and it would have possibly uncovered more adverse effects.

Conclusion

This study indicated that one could be able to prescribe Tab Phenytoin 300 mg once daily to the Indian patients as an alternative to 100 mg tid, since the adverse effects and the trough level profiles were not significantly different between the two regimens. A once daily regimen could dramatically improve the compliance of the patient. For a chronic disease like epilepsy, patient compliance is important in the overall control of the disease, the quality of life and in the prevention of the complications. It is hoped that the findings of this study will help in the overall management of the epileptic patients in India.

Acknowledgement

We would like to acknowledge Dr Kalpana Ernest, HOD Department of Pharmacology, CMC, Vellore, Dr Denise Fleming Phd, Department of Clinical Pharmacology, CMC, Vellore and Dr Fleming, Department of Clinical Biochemistry, CMC, Vellore for their support through out the study period.

References

1.
Mattson RH, Cramer JA, Colins JF. Aspects of compliance taking drugs and keeping clinical appointments. Epilepsy-Res-Suppl. 1988; 1: 111-17.
2.
Leppik IE. Variability of the phenytoin, carbamazepine and the valproate concentrations in a clinical population. Epilepsy-Res-Suppl. 1988; 1: 85-90.
3.
Buchanan RA, Kinkel AW, Smith TC. The metabolism of diphenylhydantoin (DilantinR) following a once daily administration. Neurology. 1972 Feb; 22: 126-30.
4.
Cocks DA, Critchly EM. The control of epilepsy with a single daily dose of phenytin sodium. Br-J-Clin-Pharmacol. 1975 Oct; 2(5); 449-53.
5.
Randinitis EJ, Buchanan RA, Kinkel AW. Pharmacokinetic profile of a 300 mg extended phenytoin sodium capsule (Dilantin) formulation. Epilepsia. 1990 Jul-Aug ; 31(4): 458-64.
6.
Hashimoto Y. Effect of the CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Biol- Pharm-Bull. 1996 Aug; 19(8): 1103-05.
7.
Richens A. Clinical Pharmaokintics of phenytoin. Clinical pharmacokinetics. 1979; 4(3): 153-69.
8.
Dill WA, Glazko AJ, Chang T.A. simplified benzophenone procedure for the determination of diphenylhydantoin in plasma. Clinical Chemistry. 1971; 17: 1200-01.
9.
Haerer AF, Buchanan RA. Effectiveness of single daily doses of diphenylhydantoin. Neurology. 1972 Oct; 22: 1021-28.
10.
Meyer MC, Cloyd J, Schiffer JR. Practical considerations in anticonvulsant therapy- Part-2. Am-Pharm. 1995 Sept; NS 35 (9): 31- 36,40.
11.
Atkinson AJ, Shaw JM. Pharmacokinetic study of a patient with diphenyhydantoin toxicity. Clinical Pharmacokinetics and Therapeutics. 1973; 14(4): 521-28.

DOI and Others

ID: JCDR/2012/3702:2230
Financial OR OTHER COMPETING INTERESTS:
None.
Date of Submission: Nov 24, 2011
Date of Peer Review: Jan 01, 2012
Date of Acceptance: Apr 10, 2012
Date of Publishing: Jun 22, 2012

JCDR is now Monthly and more widely Indexed .
  • Emerging Sources Citation Index (Web of Science, thomsonreuters)
  • Index Copernicus ICV 2017: 134.54
  • Academic Search Complete Database
  • Directory of Open Access Journals (DOAJ)
  • Embase
  • EBSCOhost
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Google
  • Popline (reproductive health literature)
  • www.omnimedicalsearch.com